Roivant Sciences Ltd. ROIV
Institutional shares held
496 Million
989K
calls
1.15M
puts
Total value of holdings
$5.93B
$11.8M
calls
$13.8M
puts
Market Cap
$8.41B
704,382,976
Shares Out.
Institutional ownership
70.48%
# of Institutions
308
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$852 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$826 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$797 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$422 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$350 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY23MShares$275 Million7.2% of portfolio
-
State Street Corp Boston, MA18.4MShares$220 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.2MShares$146 Million59.99% of portfolio
-
Two Seas Capital LP Rye, NY10.3MShares$123 Million43.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.19MShares$97.8 Million0.0% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
876,000
-3.8%
|
$9,636,000
$11.82 P/Share
|
|
Sep 26
2024
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
876,000
-3.8%
|
$9,636,000
$11.82 P/Share
|
|
Sep 25
2024
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
50,000
-0.22%
|
$550,000
$11.77 P/Share
|
|
Sep 25
2024
|
Keith S Manchester |
SELL
Open market or private sale
|
Direct |
134,948
-9.56%
|
$1,484,428
$11.77 P/Share
|
|
Sep 25
2024
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
415,551
-8.9%
|
$4,571,061
$11.77 P/Share
|
|
Sep 25
2024
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Direct |
991,593
-17.33%
|
$10,907,523
$11.77 P/Share
|
|
Sep 24
2024
|
Keith S Manchester |
SELL
Open market or private sale
|
Direct |
368,052
-20.68%
|
$4,048,572
$11.62 P/Share
|
|
Sep 24
2024
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
577,186
-21.73%
|
$6,349,046
$11.62 P/Share
|
|
Sep 24
2024
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Direct |
1,565,670
-21.48%
|
$17,222,370
$11.62 P/Share
|
|
Sep 23
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
250,000
-54.43%
|
$2,750,000
$11.89 P/Share
|
|
Sep 23
2024
|
Rakhi Kumar Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+35.24%
|
$750,000
$3.85 P/Share
|
|
Sep 23
2024
|
Matthew Gline CEO |
SELL
Other acquisition or disposition
|
Direct |
498,539
-2.79%
|
$5,483,929
$11.97 P/Share
|
|
Sep 23
2024
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
1,983,257
-9.99%
|
$21,815,827
$11.79 P/Share
|
|
Sep 23
2024
|
Matthew Gline CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,550,000
+7.24%
|
$4,650,000
$3.85 P/Share
|
|
Sep 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.71%
|
$120,395
$11.97 P/Share
|
|
Sep 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,087
-1.45%
|
$33,957
$11.97 P/Share
|
|
Sep 20
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.75%
|
$23,419
$11.97 P/Share
|
|
Sep 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$120,395
$11.97 P/Share
|
|
Sep 12
2024
|
Meghan Fitzgerald |
SELL
Other acquisition or disposition
|
Direct |
894
-2.95%
|
$10,728
$12.12 P/Share
|
|
Sep 12
2024
|
Epperly Melissa B, |
SELL
Other acquisition or disposition
|
Direct |
4,245
-10.44%
|
$50,940
$12.12 P/Share
|
Last 12 Months Summary
Buy / Acquisition
41M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 36.4M shares |
|---|---|
| Exercise of conversion of derivative security | 4.6M shares |
Sell / Disposition
173M
Shares
From
31
Insiders
| Payment of exercise price or tax liability | 1.04M shares |
|---|---|
| Other acquisition or disposition | 123M shares |
| Open market or private sale | 49.3M shares |
| Grant, award, or other acquisition | 38.7K shares |